Literature DB >> 2951327

Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.

J Holtz, O Sommer, E Bassenge.   

Abstract

In six conscious, trained dogs, maintained on a normal sodium intake of 2 to 4 mEq/kg/day, sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15-minute i.v. infusions of human alpha-atrial natriuretic factor. Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin. The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min. Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2951327     DOI: 10.1161/01.hyp.9.4.350

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Proceedings of the British Pharmacological Society, British Pharmacology Section. 18-20 April 1990, Sheffield. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Effect of human atrial natriuretic peptide on blood glucose concentrations and hormone stimulation during insulin-induced hypoglycaemia in healthy man.

Authors:  E Jungmann; C Konzok; E Höll; W Fassbinder; K Schöffling
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Interactions between atrial natriuretic factor and the autonomic nervous system.

Authors:  C C Lang; A D Struthers
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

4.  The measurement of norepinephrine clearance and spillover rate into plasma in conscious spontaneously hypertensive rats.

Authors:  T K Keeton; A M Biediger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-10       Impact factor: 3.000

5.  Observations on atrial natriuretic peptide, sympathetic activity and renal Ca2+ pump in diabetic and hypertensive rats.

Authors:  A Sahai; P K Ganguly
Journal:  Clin Auton Res       Date:  1993-04       Impact factor: 4.435

6.  Enhanced cardiac angiotensinogen gene expression and angiotensin converting enzyme activity in tachypacing-induced heart failure in rats.

Authors:  M Finckh; W Hellmann; D Ganten; A Furtwängler; J Allgeier; M Boltz; J Holtz
Journal:  Basic Res Cardiol       Date:  1991 Jul-Aug       Impact factor: 17.165

7.  Atrial natriuretic peptide decreases hepatic and cardiac blood content, but increases intestinal blood content in supine humans.

Authors:  J Peters; D Neuser; W Schaden; J O Arndt
Journal:  Basic Res Cardiol       Date:  1992 May-Jun       Impact factor: 17.165

8.  Noradrenaline attenuates the natriuretic effect of atrial natriuretic factor in man.

Authors:  J J McMurray; P H Seidelin; R A Brown; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.